Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
145 studies found for:    dengue
Show Display Options
RSS Create an RSS feed from your search for:
dengue
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
81 Completed Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults
Condition: Dengue Fever
Intervention: Biological: rDEN3delta30/31‐7164
82 Recruiting Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection
Condition: Dengue Fever
Intervention: Other: case/control
83 Not yet recruiting Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh
Condition: Dengue
Interventions: Biological: TV005 vaccine;   Biological: Placebo
84 Recruiting Ketotifen as a Treatment for Vascular Leakage During Dengue Fever
Conditions: Dengue Fever;   Pleural Effusion
Interventions: Drug: Ketotifen;   Drug: Placebo
85 Completed Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease
Condition: Dengue Fever
Interventions: Biological: DENV-1 PIV, 2.5 µg;   Biological: DENV-1 PIV, 5 µg
86 Active, not recruiting A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)
Condition: Dengue Fever
Interventions: Biological: Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant;   Biological: Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant;   Other: Phosphate buffered saline;   Biological: 1 µg TDENV-PIV with Alum adjuvant;   Biological: 1 µg TDENV-PIV with AS01E adjuvant
87 Recruiting The Use of Biomarkers in Predicting Dengue Outcome
Condition: Dengue
Intervention:
88 Completed Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus
Conditions: Dengue Shock Syndrome;   Dengue Hemorrhagic Fever
Interventions: Biological: DEN4 Vaccine Candidate;   Biological: DEN4 Vaccine Placebo
89 Unknown  Prospective Study of Infant Dengue
Condition: Dengue
Intervention:
90 Active, not recruiting A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
Condition: Dengue Fever
Interventions: Biological: 4 µg TDENV-PIV with Alum adjuvant;   Biological: 1 µg TDENV-PIV with AS03B1 adjuvant;   Other: Phosphate buffered saline;   Biological: 1 µg TDENV-PIV with Alum adjuvant;   Biological: 1 µg TDENV-PIV with AS01E1 adjuvant
91 Recruiting Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine
Condition: Dengue
Interventions: Biological: rDEN3∆30;   Biological: Placebo
92 Unknown  Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS)
Condition: Dengue Shock Syndrome
Interventions: Drug: Hypertonic sodium lactate;   Drug: Ringer's lactate
93 Not yet recruiting Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore
Condition: Dengue Fever
Interventions: Drug: Celgosivir;   Drug: Modipafant 50mg;   Drug: Placebo;   Drug: Modipafant 100mg
94 Withdrawn Ability of Bedside Ultrasound to Predict Progression of Severity of Disease in Dengue Fever
Conditions: Dengue;   Disease Progression
Intervention: Other: diagnostic bedside ultrasound
95 Completed Clinical Specimens Testing Program of Dengue Antigen Detection Reagents
Condition: Dengue Fever
Intervention:
96 Active, not recruiting Factors Associated With Poor Dengue Outcomes in Malaysia
Condition: Dengue Fever
Intervention:
97 Not yet recruiting Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age
Condition: Dengue
Interventions: Biological: TetraVax-DV TV005;   Biological: Placebo
98 Recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30
Condition: Dengue
Interventions: Biological: TetraVax-DV-TV005;   Biological: rDEN3Δ30;   Biological: Placebo
99 Recruiting The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico
Conditions: Zika Virus Disease (Disorder);   Dengue;   Chikungunya
Intervention:
100 Active, not recruiting Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults
Condition: Dengue
Interventions: Biological: TV005;   Biological: Placebo;   Biological: rDEN2∆30-7169

First Page    Show previous page of results Previous Page (61-80) Studies Shown (81-100) Next Page (101-120) Show next page of results    Last Page
Indicates status has not been verified in more than two years